| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1912 | 2016 |
| Dupilumab treatment in adults with moderate-to-severe atopic dermatitis LA Beck, D Thaçi, JD Hamilton, NM Graham, T Bieber, R Rocklin, JE Ming, ... New England Journal of Medicine 371 (2), 130-139, 2014 | 1520 | 2014 |
| The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 10 (3), 239-254, 2016 | 870 | 2016 |
| Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial D Thaçi, A Blauvelt, K Reich, TF Tsai, F Vanaclocha, K Kingo, M Ziv, ... Journal of the American Academy of Dermatology 73 (3), 400-409, 2015 | 667 | 2015 |
| Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose … D Thaci, EL Simpson, LA Beck, T Bieber, A Blauvelt, K Papp, W Soong, ... The Lancet 387 (10013), 40-52, 2016 | 644 | 2016 |
| Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics PJ Mease, DD Gladman, KA Papp, MM Khraishi, D Thaçi, F Behrens, ... Journal of the American Academy of Dermatology 69 (5), 729-735, 2013 | 611 | 2013 |
| Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair, D Thaçi, K Nograles, ... The Lancet 390 (10091), 276-288, 2017 | 577 | 2017 |
| Psoriasis: a possible risk factor for development of coronary artery calcification RJ Ludwig, C Herzog, A Rostock, FR Ochsendorf, TM Zollner, D Thaci, ... British Journal of Dermatology 156 (2), 271-276, 2007 | 502 | 2007 |
| Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment … M de Bruin‐Weller, D Thaçi, CH Smith, K Reich, MJ Cork, A Radin, ... British Journal of Dermatology 178 (5), 1083-1101, 2018 | 501 | 2018 |
| A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis KA Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, ... British Journal of Dermatology 175 (2), 273-286, 2016 | 498 | 2016 |
| Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised … P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ... The Lancet 389 (10086), 2317-2327, 2017 | 464 | 2017 |
| Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double … E Guttman-Yassky, HD Teixeira, EL Simpson, KA Papp, AL Pangan, ... The Lancet 397 (10290), 2151-2168, 2021 | 441 | 2021 |
| Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis K Papp, K Gordon, D Thaçi, A Morita, M Gooderham, P Foley, IG Girgis, ... New England Journal of Medicine 379 (14), 1313-1321, 2018 | 413 | 2018 |
| Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study P Rich, B Sigurgeirsson, D Thaci, JP Ortonne, C Paul, RE Schopf, ... British Journal of Dermatology 168 (2), 402-411, 2013 | 386 | 2013 |
| Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study A Blauvelt, K Reich, TF Tsai, S Tyring, F Vanaclocha, K Kingo, M Ziv, ... Journal of the american academy of dermatology 76 (1), 60-69. e9, 2017 | 376 | 2017 |
| Abrocitinib versus placebo or dupilumab for atopic dermatitis T Bieber, EL Simpson, JI Silverberg, D Thaçi, C Paul, AE Pink, Y Kataoka, ... New England Journal of Medicine 384 (12), 1101-1112, 2021 | 369 | 2021 |
| Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial E Guttman-Yassky, D Thaçi, AL Pangan, HC Hong, KA Papp, K Reich, ... Journal of Allergy and Clinical Immunology 145 (3), 877-884, 2020 | 359 | 2020 |
| Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo … AS Paller, EC Siegfried, D Thaçi, A Wollenberg, MJ Cork, PD Arkwright, ... Journal of the American Academy of Dermatology 83 (5), 1282-1293, 2020 | 356 | 2020 |
| Psoriasis patients show signs of insulin resistance S Boehncke, D Thaci, H Beschmann, RJ Ludwig, H Ackermann, ... British Journal of Dermatology 157 (6), 1249-1251, 2007 | 355 | 2007 |
| Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials KA Papp, MA Menter, M Abe, B Elewski, SR Feldman, AB Gottlieb, ... British Journal of Dermatology 173 (4), 949-961, 2015 | 316 | 2015 |
